Literature DB >> 19945026

Cushing's disease.

Xavier Bertagna1, Laurence Guignat, Lionel Groussin, Jérôme Bertherat.   

Abstract

Cushing's syndrome refers to the clinical manifestations induced by chronic exposure to excess glucocorticoids. There are three pathological conditions that can result in the chronic overproduction of endogenous cortisol in man: the most frequent is Cushing's disease where adrenocorticotropic hormone (ACTH) is overproduced by a pituitary corticotroph adenoma, rarely ACTH can be produced in an 'ectopic' manner by a non-pituitary tumour, finally cortisol can be directly over-secreted by one or (rarely) the two adrenals that have become tumourous, either benign or malignant. The positive diagnosis of Cushing's syndrome requires that chronic hypercortisolism is unequivocally demonstrated biologically, using 24-h urinary cortisol, late-evening plasma or salivary cortisol, midnight 1-mg or the classic 48-h-low-dose dexamethasone suppression test, etc., all with essentially the same diagnosis potencies. The search for the responsible tumour then relies on the assessment of the corticotroph function, and imaging: suppressed ACTH plasma levels indicate an 'adrenal' Cushing, and the responsible unilateral adrenocortical tumour is always visible at computed tomography (CT) scan, whereas its benign or malignant nature may be difficult to diagnose before surgery. Imaging can suspect bilateral 'adrenal' Cushing, when the two adrenals are small, as in the primary pigmented nodular adrenal dysplasia associated with Carney complex, or enlarged, as in the ACTH-independent macronodular adrenocortical hyperplasia. Measurable or increased ACTH plasma levels indicate either Cushing's disease or the ectopic ACTH syndrome. When the dynamics of the corticotroph function (high-dose dexamethasone suppression test, the CRH test) are equivocal, and/or the imaging is non-contributive, it may be difficult to distinguish between the two. This is the situation where sampling ACTH plasma levels in the inferior petrosal sinus may be necessary. The best treatment option of Cushing's disease is when the responsible corticotroph adenoma can be entirely removed by the trans-sphenoidal approach, with sufficient skill to preserve the normal anterior pituitary function. When it fails, all other options directed towards the pituitary (radiation therapies), or the adrenals (medications or surgery), have numerous side effects. There is at present no recognised efficient medical treatment towards the corticotroph adenoma -still an orphan disease.

Entities:  

Mesh:

Year:  2009        PMID: 19945026     DOI: 10.1016/j.beem.2009.06.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  43 in total

1.  Surgery: Remission after transsphenoidal surgery for Cushing disease.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Nat Rev Endocrinol       Date:  2010-06       Impact factor: 43.330

Review 2.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

3.  Classification, diagnosis and treatment of ACTH-independent macronodular adrenal hyperplasia.

Authors:  Heng-Chuan Su; Jun Dai; Xin Huang; Wen-Long Zhou; Bao-Xing Huang; Wan-Li Cao; Fu-Kang Sun
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

4.  Incremental healthcare resource utilization and costs in US patients with Cushing's disease compared with diabetes mellitus and population controls.

Authors:  Michael S Broder; Maureen P Neary; Eunice Chang; William H Ludlam
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

5.  White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study.

Authors:  Patricia Pires; Alicia Santos; Yolanda Vives-Gilabert; Susan M Webb; Aitor Sainz-Ruiz; Eugenia Resmini; Iris Crespo; Manel de Juan-Delago; Beatriz Gómez-Anson
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 6.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

7.  ACTH-secreting pituitary adenomas: size does not correlate with hormonal activity.

Authors:  Nestoras Mathioudakis; Courtney Pendleton; Alfredo Quinones-Hinojosa; Gary S Wand; Roberto Salvatori
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

8.  Peptic ulcer disease in endogenous hypercortisolism: myth or reality?

Authors:  Esra Hatipoglu; Asli Sezgin Caglar; Erkan Caglar; Serdal Ugurlu; Murat Tuncer; Pinar Kadioglu
Journal:  Endocrine       Date:  2015-04-21       Impact factor: 3.633

9.  The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome.

Authors:  Valentina Guarnotta; Marco C Amato; Rosario Pivonello; Giorgio Arnaldi; Alessandro Ciresi; Laura Trementino; Roberto Citarrella; Davide Iacuaniello; Grazia Michetti; Chiara Simeoli; Annamaria Colao; Carla Giordano
Journal:  Endocrine       Date:  2016-03-10       Impact factor: 3.633

10.  The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias.

Authors:  Yunze Xu; Wenbin Rui; Yicheng Qi; Chongyu Zhang; Juping Zhao; Xiaojing Wang; Yuxuan Wu; Qi Zhu; Zhoujun Shen; Guang Ning; Yu Zhu
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.